XBiotech announces first patient in phase 2 study evaluating MABp1 in patients with AD
XBiotech announced the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating MABp1 in patients with moderate to severe Atopic Dermatitis. The patient began treatment at Florida Academic Dermatology Center. May 22, 2018